Elevated circulating follistatin associates with an increased risk of type 2 diabetes

Chuanyan Wu, Yan Borné, Rui Gao, Maykel López Rodriguez, William C. Roell, Jonathan M. Wilson, Ajit Regmi, Cheng Luan, Dina Mansour Aly, Andreas Peter, Jürgen Machann, Harald Staiger, Andreas Fritsche, Andreas L. Birkenfeld, Rongya Tao, Robert Wagner, Mickaël Canouil, Mun-Gwan Hong, Jochen M. Schwenk, Emma Ahlqvist, Minna U. Kaikkonen, Peter Nilsson, Angela C. Shore, Faisel Khan, Andrea Natali, Olle Melander, Marju Orho-Melander, Jan Nilsson, Hans-Ulrich Häring, Erik Renström, Claes B. Wollheim, Gunnar Engström, Jianping Weng, Ewan R. Pearson, Paul W. Franks, Morris F. White, Kevin L. Duffin, Allan Arthur Vaag, Markku Laakso, Norbert Stefan, Leif Groop and Yang De Marinis ()
Additional contact information
Chuanyan Wu: Lund University
Yan Borné: Lund University
Rui Gao: School of Control Science and Engineering, Shandong University
Maykel López Rodriguez: Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland
William C. Roell: Lilly Research Laboratories, Eli Lilly and Company
Jonathan M. Wilson: Lilly Research Laboratories, Eli Lilly and Company
Ajit Regmi: Lilly Research Laboratories, Eli Lilly and Company
Cheng Luan: Lund University
Dina Mansour Aly: Lund University
Andreas Peter: Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen
Jürgen Machann: Institute of Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich
Harald Staiger: Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen
Andreas Fritsche: Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen
Andreas L. Birkenfeld: Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen
Rongya Tao: Boston Children’s Hospital, Harvard Medical School
Robert Wagner: Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen
Mickaël Canouil: Inserm U1283 / CNRS UMR 8199, European Genomic Institute for Diabetes (EGID), Institut Pasteur de Lille; University of Lille, Lille University Hospital
Mun-Gwan Hong: Affinity Proteomics, Science for Life Laboratory, KTH Royal Institute of Technology
Jochen M. Schwenk: Affinity Proteomics, Science for Life Laboratory, KTH Royal Institute of Technology
Emma Ahlqvist: Lund University
Minna U. Kaikkonen: University of Eastern Finland
Peter Nilsson: Lund University
Angela C. Shore: NIHR Exeter Clinical Research Facility, Royal Devon and Exeter Hospital and University of Exeter Medical School, Exeter
Faisel Khan: University of Dundee, Ninewells Hospital & Medical School
Andrea Natali: University of Pisa
Olle Melander: Lund University
Marju Orho-Melander: Lund University
Jan Nilsson: Lund University
Hans-Ulrich Häring: Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen
Erik Renström: Lund University
Claes B. Wollheim: Lund University
Gunnar Engström: Lund University
Jianping Weng: University of Science and Technology of China
Ewan R. Pearson: School of Medicine, University of Dundee
Paul W. Franks: Lund University
Morris F. White: Boston Children’s Hospital, Harvard Medical School
Kevin L. Duffin: Lilly Research Laboratories, Eli Lilly and Company
Allan Arthur Vaag: Steno Diabetes Center Copenhagen
Markku Laakso: Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland
Norbert Stefan: Institute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, University of Tübingen
Leif Groop: Lund University
Yang De Marinis: Lund University

Nature Communications, 2021, vol. 12, issue 1, 1-10

Abstract: Abstract The hepatokine follistatin is elevated in patients with type 2 diabetes (T2D) and promotes hyperglycemia in mice. Here we explore the relationship of plasma follistatin levels with incident T2D and mechanisms involved. Adjusted hazard ratio (HR) per standard deviation (SD) increase in follistatin levels for T2D is 1.24 (CI: 1.04–1.47, p

Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-021-26536-w Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-26536-w

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-26536-w

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().